STOCK TITAN

ADMA Biologics CEO Grossman sells 21,000 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

ADMA Biologics President and CEO Adam S. Grossman exercised options for 15,000 common shares on November 16, 2026, at an exercise price of $5.40 per share, then sold 21,000 common shares in two transactions at $13.72 per share. The transactions were effected under a Rule 10b5-1 trading plan entered into with Fidelity Brokerage Services LLC on November 14, 2025.

Insider Grossman Adam S
Role President and CEO
Sold 21,000 shs ($288K)
Approx. gross sale proceeds $288K
Approx. exercise cost $81K
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) F1, F8 15,000 $0.00 $0.00
Exercise Common Stock F1 15,000 $5.40 $81K
Sale Common Stock F1, F2 15,000 $13.72 $206K
Sale Common Stock F1, F2, F3, F4, F5 6,000 $13.72 $82K
Holding Common Stock F6 -- -- --
Holding Common Stock F7 -- -- --
Holdings After Transaction: Stock Option (Right to Buy) — 570,950 options (Direct); Common Stock — 2,064,777 shares (Direct); Common Stock — 1,724,383 shares (Indirect, See Footnote)
Footnotes (8)
  1. F1. Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.
  2. F2. The price reported in Column 4 is the price at which the shares were sold.
  3. F3. Includes, as of the transaction date, (i) 282,529 unvested restricted stock units ("RSUs") granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 189,017 unvested RSUs out of 252,022 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
  4. F4. (continued from footnote 3) (iii) 278,864 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 143,424 unvested RSUs out of 573,695 RSUs granted on March 6, 2023, vesting quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
  5. F5. (continued from footnote 4) and (v) 1,170,943 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
  6. F6. These shares are owned by Areth, LLC ("Areth"). The Reporting Person is a control person of Areth.
  7. F7. These shares are owned by Hariden, LLC ("Hariden"). The Reporting Person is the managing member of Hariden.
  8. F8. The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.
Shares acquired through option exercise 15,000 shares November 16, 2026
Option exercise price $5.40 per share Exercise of options for common shares on November 16, 2026
Shares sold 21,000 shares Two transactions on November 16, 2026, at $13.72 per share
Sale price $13.72 per share Both reported sales on November 16, 2026
Common shares owned 1,170,943 shares As of November 16, 2026
Stock option shares following transaction 570,950 shares Reported following the November 16, 2026 option transaction
Rule 10b5-1 trading plan regulatory
"effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
restricted stock units financial
"282,529 unvested restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
net settlement upon vesting financial
"prior net settlement upon vesting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ADMA shares did CEO Adam S. Grossman sell, and at what price?

Grossman sold 21,000 common shares in two transactions at $13.72 per share on November 16, 2026. The transactions were effected under a Rule 10b5-1 trading plan entered into with Fidelity Brokerage Services LLC on November 14, 2025.

What were the terms of Adam S. Grossman's ADMA option exercise?

Grossman exercised options for 15,000 common shares at $5.40 per share on November 16, 2026. The option was granted on February 26, 2024, and expires on February 26, 2034. Its vesting schedule provided for 25% of 217,737 underlying shares to vest on February 26, 2025, with the remaining 75% vesting monthly through February 26, 2028.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Grossman Adam S

(Last)(First)(Middle)
C/O ADMA BIOLOGICS, INC.
465 STATE ROUTE 17

(Street)
RAMSEY NEW JERSEY 07446

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
ADMA BIOLOGICS, INC. [ ADMA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
President and CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/16/2026M15,000(1)A$5.42,085,777D
Common Stock11/16/2026S15,000(1)D$13.72(2)2,070,777D
Common Stock11/16/2026S6,000(1)D$13.72(2)2,064,777(3)(4)(5)D
Common Stock1,143,426ISee Footnote(6)
Common Stock580,957ISee Footnote(7)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$5.411/16/2026M15,000(1) (8)02/26/2034Common Stock15,000$0570,950D
Explanation of Responses:
1. Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.
2. The price reported in Column 4 is the price at which the shares were sold.
3. Includes, as of the transaction date, (i) 282,529 unvested restricted stock units ("RSUs") granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 189,017 unvested RSUs out of 252,022 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
4. (continued from footnote 3) (iii) 278,864 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 143,424 unvested RSUs out of 573,695 RSUs granted on March 6, 2023, vesting quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
5. (continued from footnote 4) and (v) 1,170,943 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
6. These shares are owned by Areth, LLC ("Areth"). The Reporting Person is a control person of Areth.
7. These shares are owned by Hariden, LLC ("Hariden"). The Reporting Person is the managing member of Hariden.
8. The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.
/s/ Adam S. Grossman, by Michael A. Goldstein as Attorney-in-fact11/16/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading